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Use of Optical Coherence Tomography (OCT) for Characterization of Carotid
Plaque In Patients with Severe Asymptomatic Carotid Stenosis
Mehmet Cilingiroglu1, Mark Wholey1
1UPMC Heart and Vascular Institute, Pittsburgh, PA
Background: Carotid artery related stroke is mainly an embolic disease that has been
associated with inflammation, plaque rupture, and thrombus formation in vulnerable
atherosclerotic plaque. Almost, two-thirds of these strokes affect patients who are
previously asymptomatic. Estimation of the degree of stenosis in a carotid lesion based on
angiography is a poor predictor of clinical outcome. We propose that stroke risk may be
best predicted by plaque morphology in these asymptomatic lesions using OCT with its
unique fine imaging resolution.
Methods: We have performed OCT imaging of carotid plaques in 22 consecutive
asymptomatic patients with severe carotid artery stenosis. Detailed analysis showed
various features of high-risk vulnerable plaque such as thin-cap fibroatheroma, plaque
rupture, intraluminal thrombus, calcifications in some (n13) while the remaining had
none of these features (n9). Periprocedural events rates were compared between two
groups.
Results: Patients with high-risk vulnerable plaque features had more periprocedural
events, while the patients without these features had no events.
Conclusions: OCT can be used safely and effectively to identify high-risk vulnerable
plaque features in asymptomatic patients with severe carotid artery stenosis for further risk
stratification and optimal treatment strategy such as carotid artery stenting versus carotid
endarderectomy.
TCT-191
Percutaneous Transluminal Angioplasty And Stenting Of Extracranial
Vertebral Artery Stenoses
Isabelle Henry1, Amira Benjelloun2, Michel Henry3
1Polyclinique Bois Bernard, BOIS BERNARD, France, 2Clinique Coeur et
Vaisseaux, RABAT, Morocco, 3Cabinet de cardiologie, nancy, France
Background: To evaluate the safety and efficiency of vertebral angioplasty and stenting
(VAS) in symptomatic patients.
Methods: Material and Methods: 102 angioplasties in 96 pts (M:72) mean age 68,3 6,7
years (22-84) left 58. All pts had multivascular diseases: carotid (CA):63, subclavian
(SA): 26, coronary:64. . . . Atheromatous lesions: 100, inflammatory: 2. Mean lesion
length: 9,6	/ 2,8 mm. Mean % stenosis 83.2 7.7, mean arterial diameter : 4,8 0,6
mm (4-6). 94 lesions at VO segment (ostium), 6 at V1 and 2 at V2 segments. Indications
for angioplasty: dizziness (96), bilateral weakness (11), visual changes (11), diplopia (10),
drop attacks (20), TIA (13), ataxia (5). A protection device (filter) used in 10 pts. 20 SA
angioplasties performed at the same time of VAS, 8 CA. All angioplasties performed by
femoral approach, 4 by brachial approaches after failure of femoral approach. (2
successes).
Results: Technical success 100/102 (98%). 6 lesions treated by angioplasty alone: 3 VO
(first 3 pts. 2 V1, 1 V2 lesion). 1 pt (inflammatory disease) treated by cutting balloon
alone. 93 lesions treated with stents (direct stenting: 78). Peripheral balloon expandable
stents (n23), self expandable stents (n4 for 3 V1 and one V2 lesions). 70 coronary
stents (14 DES). 1 pt developed a TIA during the procedure. No neurological complica-
tions at 30 days Clinical success 94/96 (98%) Post-procedure arterial diameter: 4,55 0,8
mm (4-6). Mean residual stenosis 2,2  3,5 %. In 10 pts treated with protection devices,
visible debris removed in 7 (5 Filterwire, 2 Fibernet) with the same amount of debris as
during Carotid Stenting) 7 pts (8%) developed a symptomatic restenosis during the
follow-up (mean: 31.4.28.9 months), 3 after PTA alone, 4 after PTA and stent (1
occlusion treated medically, 6 stenoses successfully treated with PTA). No restenosis after
DES implantation at 1 year.
Conclusions: VAS can be performed safely and effectively with a high technical success
rate, a low complication rate, a low restenosis rate and a durable clinical success in
patients with symptomatic VA stenosis. Stents seem to improve immediate and long-term
results. The role of protection devices and D.E.S has to be discussed.
TCT-192
Vertebral Angioplasty Stenting. Are Protection Devices Useful?
Isabelle Henry1, Amira Benjelloun2, Michel Henry3
1Polyclinique Bois Bernard, BOIS BERNARD, France, 2Clinique Coeur et
Vaisseaux, RABAT, Morocco, 3Cabinet de cardiologie, nancy, France
Background: It is now clear that atheroemboli are the rule in any intervention in
atherosclerotic disease and seems the root cause of many procedural complications.
Embolic protection devices (EPD) reduce the number of cerebral emboli during carotid
angioplasty stenting (CAS).Recent studies have shown a high incidence of emboli during
Vertebral Angioplasty Stenting (V.A.S) and a comparable frequency and amount of
captured emboli during V.A.S and CAS. Neurological complications after V.A.S are not
frequent but could be devastating. So the use of EPD for VAS may be advisable and
should reduce the neurological complications during V.A.S
Methods: We retrospectively determined rates of technical success and one month stroke
and death associated with stent placement by using EPD (Filterwire and Fibernet filter in
patients with symptomatic ostial VA stenoses. Technical success was defined as
successful EPD deployment and stent placement, successful EPD retrieval and a residual
stenosis 30%. 30 day outcomes included any stroke and death. The new EPD (Fibernet)
allows capture of debris of 40 microns without compromising the flow. Its retrieval
catheter is an aspiration catheter allowing meticulous cleaning of the vessel and of the
dilated area
Results: In a series of 102 VAS, 10 patients treated with EPD. Mean age 69 y. (63-80).
Male: 8, left 6. Mean % stenosis 80,96,8. Mean arterial diameter: 4,8  0,5mm.
Femoral approach used in all cases. Filterwire :8 patients, Fibernet: 2. Technical success
was achieved for the 10 patients. Postprocedure residual stenoses: 43%. Visible debris
were removed in 70% of cases (Filterwire:5 and Fibernet:2). Filter deployment time: 10
mm (7-13 mm). No stroke or death observed at one month. With Fibernet mean debris
area: 184 mm2. (aspirated debris : 114mm2, debris in the filter 70 mm2) Debris analysis
will be reported. These results are comparable to the results obtained in CAS.
Conclusions: The present study demonstrates the feasibility and safety of VAS using
EPD. Further studies are required to determine the exact role of EPD and their indications
in VAS. It seems that the results obtained in VAS are comparable to those obtained after
CAS.
TCT-193
Use Of Drug-Eluting Balloon For The Treatment Of In-stent Restenosis After
Carotid Artery Stenting
Piero Montorsi1, Antonio Bartorelli2, Franco Fabbiocchi1, Stefano Galli1,
Alessandro Lualdi1, Paolo Ravagnani1, Giovanni Teruzzi1, Daniela Trabattoni1,
Sarah Troiano3
1Centro Cardiologico Monzino, IRCCS, Milan, Italy, 2Associate Professor
University of Milan-Centro Cardiologico Monzino, Milan, Italy, 3University of
Milan, Milan, Italy
Background: In-stent restenosis (ISR) after carotid artery stenting (CAS) is a rare event.
Endovascular treatment is considered for significant ISR (80% diameter stenosis by
Doppler US). Despite favorable acute results, recurrent ISR ranges between 0 and 50%.
Evidence of DEB effectiveness for coronary and peripheral ISR treatment is accumulat-
ing. We assessed the safety and efficacy of DEB in ISR after CAS.
Methods: Significant ISR occurred in 11/803 (1.3%) consecutive CAS procedures at a
median F/U of 624580 days. In 7 pts (6 internal and 1 common carotid arteries), DEB
(In.Pact Admiral,Invatec-Medtronic,Italy) treatment (single 3-minute inflation) was per-
formed after standard predilation with distal cerebral protection. DEB size was selected by
IVUS (1:1 stent to DEB size ratio). Post-DEB, patients were treated with double
antiplatelet therapy for 3 months. Acute and long-term clinical outcomes were obtained in
all pts.
Results: Technical and procedural success was 100%. Angiographic stenosis decreased
from 835% to 186%. Minimal lumen area by IVUS increased from 3.21.8 to
12.62.1mm2 (p0.001), stent area was unchanged (from 17.54.7 to 17.34.7mm2)
and restenosis area decreased from 13.65.8 to 4.63.3mm2 (p0.001). At a F/U of
41252 days (range 343-455), no clinical event occurred. Average Doppler Peak Systolic
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Velocity (PSV) decreased from 40.97 m/s to 0.900.14 m/s. The 6- and 12-month PSV
values after DEB were significantly lower as compared to those obtained after CAS at the
same time intervals(Figure).
Conclusions: DEB treatment of ISR after CAS is feasible. Initial results show safety and
effectiveness.
TCT-194
Impact of Asymptomatic new Cerebral Lesions in DW- MRI after Carotis
Artery Stenting on Long Term Prognosis
Klaudija Bijuklic1, Andreas Wandler2, Thilo Tuebler3, Joachim Schofer4
1Medical Care Center, Hamburg, Germany, 2Medical Care Center Prof Mathey,
Prof Schofer, Hamburg, Germany, 3Medical Care Center Prof. Mathey, Prof.
Schofer, Hamburg, Germany, 4Medicare center Prof Mathey, Prof Schofer,
Hamburg University Cardiovascular Center, Hamburg, Germany
Background: After embolic protected CAS, new cerebral ischemic lesions have been
reported in up to 70 % of patients. There impact on long-term prognosis after CAS is
unknown. Aim of the study was to evaluate the impact of new asymptomatic cerebral
ischemic lesions, found in diffusion weighted magnetic resonance imaging (DWMRI)
after embolic protected carotid artery stenting (CAS), on long-term prognosis.
Methods: 837 consecutive patients who had an embolic protected CAS without
peri-procedural complications and had a DWMRI before and 24 hours after the procedure
were included. Cox Regression analyses were performed to identify independent risk
factors for long-term major adverse cerebral and cardiovascular events (MACCE)
including patient-, lesion-, and procedural characteristics as well as the result of the
DWMRI.
Results: The follow-up rate was 91 %. At a mean follow up of 779.5  535.8 days.
MACCE occurred in 6.04 % of the patients. Diabetes was the only significant independent
predictor for MACCE. Asymptomatic ischemic cerebral lesions after CAS were not
associated with MACCE during long-term FU.
Conclusions: In patients who underwent uncomplicated embolic protected CAS,only
diabetes was predictive for long-term MACCE, whereas asymptomatic ischemic embolic
events during CAS had no impact on long-term outcome.
TCT-195
Novel Quantitative Virtual Histology Parameters in the Asymptomatic and
Symptomatic Carotid Atherosclerotic Plaque Imaging: Data from the First
222 Patients in CRACK-VH Study
Piotr Musialek1, Lukasz Tekieli2, Piotr Pieniazek2, Adam Mazurek2,
Wladyslaw Dabrowski2, Anna Kablak-Ziembicka2, Tadeusz Przewlocki2,
Anetta Undas2, Krzysztof Zmudka2, Wieslawa Tracz2, Piotr Podolec2
1Jagiellonian University Institute of Cardiology, John Paul II Hospital, Krakow,
Poland, Krakow, Poland, 2Jagiellonian University Institute of Cardiology, Krakow,
Poland
Background: Internal carotid artery stenosis (CS) degree is a poor marker of symptom
risk, and plaque morphology might play an important role. IVUS offers high-resolution
(axial0.12mm for 20MHz transducer) plaque imaging; nevertheless, phenotypic virtual
histology (VH-IVUS) carotid plaque classification was shown to be prone to between-
center and between-observer image interpretation variability.
Methods: We developed and implemented a novel Q-IVUS software-based algorithm for
detailed quantitative CS plaque VH-IVUS analysis to supplement the conventional
phenotypic plaque classification. Following inter-transducer and inter-observer reproduc-
ibility validation (n21, separate communication), we employed the QVH-IVUS ’peak’
algorithm (including standard - total component value per plaque cross-sectional area, PA;
and novel parameters - eg, minimal fibrous cap thickness, confluent necrotic core area,
thickness and arc) to evaluate 222 index CS lesions in 222 consecutive patients (age
47–83y, 62.6% men, 68.9% with h/o CS-attributable symptoms, S) presenting with
CS50% in the context of potential revascularization. Use of EPD for CS imaging (67%)
was left to operator (filters 
 ¾, proximal 
 1⁄4).
Results: Table; values are peakSEM per PA; abstract p values are for Total Asympt vs.
Total Sympt CS lesions. MLAminimal lumen area, ASarea stenosis, PBplaque
burden, FCfibrous cap, NCnecrotic core, FFfibro-fatty, Cadense calcium,
FTfibrotic).
Conclusions: QVH-IVUS ’peak’ image analysis of the carotid atherosclerotic plaque
revealed significant inter-group differences in novel QVH-IVUS plaque parameters,
including lower minimal FC thickness and higher confluent NC-area, -thickness and -arc,
and higher peak confluent Ca-area in S lesions. Further work will test the role of
QVH-IVUS ’peak’ image analysis algorithm in identifying the asymptomatic CS lesions
at risk of symptomatic transformation.
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TCT-196
Chronic Cerebrospinal Venous Insufficiency: The Association Between the
Extent Of Extracranial Venous Anomalies and Clinical Severity and Duration
of Multiple Sclerosis.
Juraj Madaric1, Andrej Klepanec1, Rastislav Bazik1, Marek Toth1,
Terezia Urlandova1, Jana Margitfalviova1, Juraj Mikulas1, Erika Drangova1,
Daniela Hladikova1, Tibor Balazs1, Vladimir Neuschl2, Ivan Vulev1
1National Cardiovascular Institute, Bratislava, Slovakia, 2Institute of Diagnostic
Imaging, Trnava, Slovakia
Background: Chronic cerebrospinal venous insufficiency (CCSVI) characterized by
stenoses or obstructions of the internal jugular veins (IJV) and/or azygos vein (AZY), has
been reported to be associated with multiple sclerosis (MS). However, such association is
a matter of debate. The aim of our retrospective analysis was to determine the relationship
between the extent of extracranial venous pathology and clinical severity of MS.
Methods: We analyzed 50 consecutive patients (pts) with relapsing-remitting (32 pts)
and secondary progressive (18 pts) clinical course of MS (age 3810 years, M:F15:35)
scheduled for duplex ultrasound (DUS), invasive phlebography, and eventual endovas-
cular procedure of IJV and/or AZY. The extent of stenotic/obstructive process of IJV, and
AZY, or IJV reflux, were graded by combination of invasive phlebography and duplex
ultrasound as negative (group A), unilateral/focal stenosis/regurgitation (group B), or
bilateral/multifocal stenoses/regurgitation (group C). The clinical severity of MS was
evaluated by expanded disability disease scoring (EDSS). The study was approved by the
local scientific and ethical committee.
Results: Out of 50 analyzed pts (mean EDSS 3.72.4) there were 10 pts with negative
DUS and venous phlebography pathology (20%), 16 pts with unilateral/focal venous
pathology (32%), and 24 pts with bilateral/multifocal pathology (48%). The 20 cases were
treated by balloon angioplasty alone, whereas the stenting of at least one vein was required
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